Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”

Stefanie L. Groenland; Dieuwertje R. Geel; Jos H. Beijnen; Egbert F. Smit; Alwin D.R. Huitema; Neeltje Steeghs

doi:10.1002/cpt.2372

Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”

Stefanie L. Groenland
, Dieuwertje R. Geel
, Jos H. Beijnen
, Egbert F. Smit
, Alwin D.R. Huitema
, Neeltje Steeghs

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	1164
Number of pages	1
Journal	Clinical Pharmacology and Therapeutics
Volume	110
Issue number	5
DOIs	https://doi.org/10.1002/cpt.2372
Publication status	Published - Nov 2021
Externally published	Yes

Access to Document

10.1002/cpt.2372

Cite this

@article{c6e9c425c17b4d2bb07cb2106660ac2b,

title = "Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”",

author = "Groenland, \{Stefanie L.\} and Geel, \{Dieuwertje R.\} and Beijnen, \{Jos H.\} and Smit, \{Egbert F.\} and Huitema, \{Alwin D.R.\} and Neeltje Steeghs",

note = "Funding Information: No funding was received for this work.",

year = "2021",

month = nov,

doi = "10.1002/cpt.2372",

language = "English",

volume = "110",

pages = "1164",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "5",

}

Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”. / Groenland, Stefanie L.; Geel, Dieuwertje R.; Beijnen, Jos H. et al.
In: Clinical Pharmacology and Therapeutics, Vol. 110, No. 5, 11.2021, p. 1164.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”

AU - Groenland, Stefanie L.

AU - Geel, Dieuwertje R.

AU - Beijnen, Jos H.

AU - Smit, Egbert F.

AU - Huitema, Alwin D.R.

AU - Steeghs, Neeltje

N1 - Funding Information: No funding was received for this work.

PY - 2021/11

Y1 - 2021/11

UR - https://www.scopus.com/pages/publications/85112387765

U2 - 10.1002/cpt.2372

DO - 10.1002/cpt.2372

M3 - Letter

C2 - 34387356

AN - SCOPUS:85112387765

SN - 0009-9236

VL - 110

SP - 1164

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 5

ER -